©2022 Stanford Medicine
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Trial ID: NCT00352027
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma
- Patient is less than or equal to 21 years of age
- Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma
- Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal
involvement (3 or more sites), or bulky mediastinal adenopathy.
- Patients with favorable risk features
- Patients with unfavorable risk features
- Patients who have received prior therapy for Hodgkin lymphoma.
drug: Nitrogen Mustard
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs